IFRX vs. SLS, LPTX, ANEB, DERM, ASRT, SPRO, YS, TPST, HOOK, and MNOV
Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include SELLAS Life Sciences Group (SLS), Leap Therapeutics (LPTX), Anebulo Pharmaceuticals (ANEB), Journey Medical (DERM), Assertio (ASRT), Spero Therapeutics (SPRO), YS Biopharma (YS), Tempest Therapeutics (TPST), Hookipa Pharma (HOOK), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry.
SELLAS Life Sciences Group (NASDAQ:SLS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
SELLAS Life Sciences Group presently has a consensus price target of $3.00, indicating a potential upside of 105.48%. InflaRx has a consensus price target of $13.50, indicating a potential upside of 915.04%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than SELLAS Life Sciences Group.
SELLAS Life Sciences Group has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
SELLAS Life Sciences Group's return on equity of -40.10% beat InflaRx's return on equity.
InflaRx received 222 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 64.09% of users gave InflaRx an outperform vote while only 58.82% of users gave SELLAS Life Sciences Group an outperform vote.
SELLAS Life Sciences Group has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 1.6% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, InflaRx had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 2 mentions for InflaRx and 0 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.50 beat InflaRx's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media.
Summary
InflaRx beats SELLAS Life Sciences Group on 13 of the 17 factors compared between the two stocks.
Get InflaRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
